stockrow
Friday 6 November 2026
Export BDSX’s income statement to Excel — free account
Biodesix, Inc.
BDSX Healthcare Diagnostics & Research
Biodesix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88.5 million, up 24.1% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- +35.3%
- Free cash flow
- +12.8%
- Total debt
- +0.05%
Quarter to September 2026, against a year earlier
11.23
8.61
−43.40%
Follow BDSX
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 5 | 5 | 4 |
+8 more TTM periods Free account |
| (778.89%) | (540.01%) | (316.53%) | (383.09%) | ||
| (29.65%) | (30.33%) | (35.34%) | (38.18%) | ||
ROIC |
(44.84%) | (49.60%) | (51.87%) | (67.00%) | |
Return on Tangible Assets |
(52.58%) | (53.31%) | (63.14%) | (88.39%) | |
Average Days of Receivables |
31.63 | 32.31 | 36.08 | 37.27 | |
Free Cash Flow per Share |
(1.81) | (1.98) | (2.61) | (3.14) | |
Free Cash Flow |
(19.26) | (20.40) | (25.25) | (23.67) | |
Capital Expenditures |
(1.10) | (0.57) | (0.41) | (0.40) | |
| Other line items | |||||
Cash ROIC |
(22.86%) | (23.73%) | (31.10%) | (37.01%) | |
Accounts Receivable Turnover |
9.66 | 12.43 | 11.21 | 10.03 | |
Accounts Payable Turnover |
0.00 | 7.02 | 5.24 | 6.34 | |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 43.78 | 77.38 | 67.24 | |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
11.68% | 11.93% | 12.92% | 13.56% | |
Selling, General and Administrative Expense of Revenue |
89.36% | 90.57% | 95.07% | 98.92% | |
Share Based Compensation of Revenue |
3.67% | 3.95% | 4.46% | 4.68% | |
Interest Coverage |
— | (2.55) | (3.11) | (3.61) | |
Operating CF/Net income |
0.67 | 0.71 | 0.78 | 0.66 | |
Depreciation/Fixed assets |
0.00 | 0.29 | 0.29 | 0.28 | |
Capex/Depreciation |
0.00 | (0.08) | (0.06) | (0.06) | |
Revenue per Share |
9.87 | 10.00 | 9.95 | 11.72 | |
Operating CF per Share |
(1.70) | (1.93) | (2.57) | (3.08) | |
Capex per Share |
(0.10) | (0.06) | (0.04) | (0.05) | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026